Blockage of complement regulators in the conjunctiva and within the eye leads to massive inflammation and iritis

Immunology

Volumn 104, Issue 4, 2001, Pages 423-430

  Bardenstein, David S ^a   Cheyer, Christopher J ^a   Lee, Chieh ^a   Cocuzzi, Enzo ^a   Mizuno, Masashi ^b   Okada, Noriko ^b   Medof, M Edward ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5I2 ANTIGEN; ANTIGEN; CD59 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C3B; DECAY ACCELERATING FACTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 ANTIBODY; MEMBRANE COFACTOR PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5I2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; BLOCKING FACTOR; COMPLEMENT ACTIVATION; CONJUNCTIVA; CONJUNCTIVITIS; CONTROLLED STUDY; EYE PROTECTION; EYELID; IMMUNOHISTOCHEMISTRY; IRIS; IRITIS; NECROSIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RAT; STROMA; TISSUE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD59; ANTIGENS, SURFACE; COMPLEMENT ACTIVATION; CONJUNCTIVA; CONJUNCTIVITIS; EYE; IMMUNE TOLERANCE; IMMUNOGLOBULIN FAB FRAGMENTS; IRITIS; MICE; NEUTROPHIL INFILTRATION; RATS; RECEPTORS, CELL SURFACE; RECEPTORS, COMPLEMENT;

EID: 0035677958     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2001.01316.x     Document Type: Article

References (47)

1. The molecular basis for paroxysmal nocturnal hemoglobinuria
2. The control of homologous lysis
3. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes
4. Surface membrane expression by human leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system
5. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement
6. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria
7. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b
8. Decay-accelerating factor is present on cultured human umbilical vein endothelial cells
9. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids
10. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland
11. Localization of the complement membrane attack complex inhibitor (CD59) in human conjunctiva and lacrimal gland
12. Differential expression of the complement regulatory proteins in the human eye
13. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria
14. Distribution of hemolytic complement in the normal cornea
15. Hemolytic complement activity in normal human donor corneas
16. Cell surface regulators of complement, 5I2 antigen, and CD59, in the rat eye and adnexal tissues
17. Complement inhibitor of rat cell membrane resembling mouse Crry/p65
18. Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement
19. Tissue distribution of complement regulatory membrane proteins in rats
20. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor
21. Activation of mouse complement by monoclonal mouse antibodies
22. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies
23. Blocking of conjunctival complement regulatory proteins causes inflammatory cell infiltration
24. Localization of decay accelerating factor in normal and diseased kidneys
25. Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor
26. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria
27. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor
28. H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement
29. Amelioration of the lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor
30. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b
31. Episcleritis and scleritis. A study of their clinical manifestations and association with rheumatoid arthritis
32. The coexistence of Sjogren's syndrome and systemic lupus erythematosus
33. Ocular cicatricial pemphigoid with granular IgA and complement deposition
34. Autoimmune phenomena in ocular cicatricial pemphigoid
35. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid
36. Alternate pathway activation of complement in a Proteus mirabilis ulceration of the cornea
37. Activation of the alternative complement pathway by intraocular lenses
38. Immunohistochemical staining of retrobulbar adipose tissue in Graves' ophthalmopathy
39. IgG, IgA and C3 deposits in the extra-thyroidal manifestations of autoimmune Graves' disease: Their in vitro solubilization by intravenous immunoglobulin
40. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): Preferential expression in testicular germ cells
41. In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats
42. The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a
43. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation
44. The complement system
45. Inflammation of periocular and ocular tissues after blockage of complement regulatory protein function
46. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins
47. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins